[Therapy of mixed urinary incontinence].
The therapy of mixed urinary incontinence is still discussed controversially. Surgical procedures were seen as a minor opinion in these cases, because the urge-symptoms remain stable or even become worse after incontinence-surgery. We here present a prospective-randomized double-blinded multi-center trial with Tolterodine extended-release 4 mg once daily in 410 female patients with mixed incontinence treated in Germany. After 8 weeks of treatment we saw a nearly 60% significant regression of the symptoms of mixed incontinence. Therefore the anticholinergic treatment with tolterodine extended-release of women is a successful treatment option in mixed incontinence.
Goepel
M
M
Klinik für Urologie und Kinderurologie, Klinikum Niederberg, Akad. Lehrkrankenhaus der Universität Duisburg-Essen, Velbert. goepel@klinikum-niederberg.de
D000328:Adult; D000368:Aged; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D003408:Cresols / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D005858:Germany; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D010665:Phenylpropanolamine; D011446:Prospective Studies; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D014563:Urodynamics / Q000187:drug effects
D001559:Benzhydryl Compounds; D003408:Cresols; D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate